COVID-19 Vaccine Knowledge, Attitude, Acceptance and Hesitancy among Pregnancy and Breastfeeding: Systematic Review of Hospital-Based Studies.

Publication date: Nov 07, 2023

The risk of unfavourable outcomes for SARS-CoV-2 infection is significant during pregnancy and breastfeeding. Vaccination is a safe and effective measure to lower this risk. This study aims at reviewing the literature concerning the anti-SARS-CoV-2 vaccine’s acceptance/hesitancy among pregnant and breastfeeding women attending hospital facilities. A systematic review of literature was carried out. Hospital-based observational studies related to vaccination acceptance, hesitancy, knowledge and attitude among pregnant and breastfeeding women were included. Determinants of acceptance and hesitancy were investigated in detail. Quality assessment was done via the Johann Briggs Institute quality assessment tools. After literature search, 43 studies were included, 30 of which only focused on pregnant women (total sample 25,862 subjects). Sample size ranged from 109 to 7017 people. Acceptance of the SARS-CoV-2 vaccine ranged from 16% to 78. 52%; vaccine hesitancy ranged between 91. 4% and 24. 5%. Fear of adverse events for either the woman, the child, or both, was the main driver for hesitancy. Other determinants of hesitancy included religious concerns, socioeconomic factors, inadequate information regarding the vaccine and lack of trust towards institutions. SARS-CoV-2 vaccine hesitancy in hospitalized pregnant women appears to be significant, and efforts for a more effective communication to these subjects are required.

Open Access PDF

Concepts Keywords
Basel adverse events
Breastfeeding communication
Driver COVID-19
Hospital pregnancy
Unfavourable SARS-CoV-2
vaccine hesitancy

Semantics

Type Source Name
disease VO COVID-19 vaccine
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease VO vaccination
disease VO effective
disease VO vaccine
disease IDO quality
disease VO pregnant women
disease VO LACK
drug DRUGBANK Coenzyme M
disease VO population
disease MESH vaccine preventable diseases
disease VO vaccinated
disease VO effectiveness
disease MESH uncertainty
drug DRUGBANK Methionine
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO process
disease VO USA
disease VO protocol
drug DRUGBANK Indoleacetic acid
disease IDO country
disease MESH Emergency
drug DRUGBANK Troleandomycin
disease IDO history
disease VO unvaccinated
drug DRUGBANK Aspartame
disease VO monthly
disease MESH pregnancy outcomes
disease MESH chronic disease
disease MESH influenza
disease MESH complications
disease IDO susceptibility

Original Article

(Visited 1 times, 1 visits today)